EUVIMEDEUVIMED entdecken
Multizentrische Studie

Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real‐Life Study

Lucia Farina, Alessandro Noto, Antonella Aiello, Marina Motta, Andrea Ferrario, Riccardo Moia iD, Lydia Scarfò, Marina Deodato iD, Michele Merli, Silva Ljevar, Giancarlo Pruneri, Cristiana Carniti iD und 1 weitere

Hematological Oncology · 2026-03 · 44 (2)

DOI: 10.1002/hon.70176 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, online erschienen am 10.02.2026. Verfasst von Lucia Farina und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Neoplasm, Residual. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Associazione Italiana Contro le Leucemie - Linfomi e Mieloma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Measurable residual disease (MRD) status in chronic lymphocytic leukemia (CLL) patients treated with venetoclax is a predictive factor of outcome in clinical trials. This multicenter prospective study was aimed to show the feasibility of MRD assessment in the real‐life setting and to confirm the results of clinical trials. Forty‐four patients were enrolled: 43% had 17p deleted and/or TP53 mutated (del17p/TP53mut), 62% had complex karyotype, and 65% of patients were previously treated with B‐cell receptor inhibitor (BCRi). MRD was evaluated by 8‐color flow cytometry (FC) on peripheral blood (PB) every 3 months from therapy start and samples with 10 −4 CLL cells were considered as undetectable (uMRD). PB‐uMRD patients were evaluated on bone marrow (BM). In 23 patients venetoclax was combined with Rituximab (VR). Median follow‐up was 39.47 months (range 31.02–43.32). Median number of PB samples for each patients was 5 (IQR 4–7). Undetectable MRD on PB at any timepoint was obtained in 34/40 patients (85%): 82% in venetoclax monotherapy (Vmono) and 86.9% in VR group. Concordance of PB/BM samples was 92% at 24 months. No significant difference in uMRD rates was detected based on del17p/TP53mut and number of previous therapies. Three‐year progression‐free survival (PFS) for Vmono and VR was 53.5% and 55%. Median PFS in del17pl/TP53mut was 29.8 and 34 months in Vmono and VR respectively. Landmark analysis based on 9‐month MRD showed a trend towards a better PFS in uMRD patients. Median PFS was 21.7 and 13.04 months in 24‐month uMRD and detectable MRD patients after VR, respectively (log rank p = 0.0309). In conclusion, in these high‐risk relapsed/refractory CLL patients who were MRD‐monitored in the context of a real‐life study the results were similar compared to published data in more selected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellBridged Bicyclo Compounds, HeterocyclicSulfonamidesNeoplasm, ResidualAntineoplastic AgentsHumansFemaleProspective StudiesMaleAgedMiddle AgedAged, 80 and overLongitudinal StudiesAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

chronic lymphocytic leukemiaminimal residual diseasevenetoclax

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic Agents

Autor:innen und Institutionen

  • Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • S.C. Ematologia, ASST Spedali Civili, Brescia, Italy.
  • Hematology, ASST dei Sette Laghi-Ospedale di Circolo, Varese, Italy.
  • Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and AOU Maggiore della Carità, Novara, Italy.
  • School of Medicine, Università Vita-Salute San Raffaele, Milano, Italy.

ORCID-Profile: Riccardo Moia, Marina Deodato, Cristiana Carniti

Förderung

  • Associazione Italiana Contro le Leucemie - Linfomi e Mieloma

Zitieren

APA

Farina, L., Noto, A., Aiello, A., Motta, M., Ferrario, A., Moia, R., Scarfò, L., Deodato, M., Merli, M., Ljevar, S., Pruneri, G., Carniti, C., & Corradini, P. (2026). Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real‐Life Study. Hematological Oncology, 44(2). https://doi.org/10.1002/hon.70176

Vancouver

Farina L, Noto A, Aiello A, Motta M, Ferrario A, Moia R, et al. Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real‐Life Study. Hematological Oncology. 2026;44(2). doi:10.1002/hon.70176

BibTeX
@article{Farina2026,
  author = {Farina, Lucia and Noto, Alessandro and Aiello, Antonella and Motta, Marina and Ferrario, Andrea and Moia, Riccardo and Scarfò, Lydia and Deodato, Marina and Merli, Michele and Ljevar, Silva and Pruneri, Giancarlo and Carniti, Cristiana and Corradini, Paolo},
  title = {Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real‐Life Study},
  journal = {Hematological Oncology},
  year = {2026},
  volume = {44},
  number = {2},
  doi = {10.1002/hon.70176}
}
Kostenlos starten →